Compassionate Use of Stiripentol in Dravet Syndrome
- Conditions
- Dravet Syndrome
- Registration Number
- NCT01835314
- Lead Sponsor
- University of Colorado, Denver
- Brief Summary
Compassionate use of Stiripentol in Dravet Syndrome. This is a treatment protocol, not a research study, therefore children will only be monitored on a clinical basis for seizure improvement predominantly by parent and caregiver report.
- Detailed Description
This is a treatment protocol for compassionate use, not a research study, therefore children will only be monitored on a clinical basis for seizure improvement predominantly by parent and caregiver report.
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Stiripentol's anticonvulsant effects in Dravet Syndrome patients?
How does Stiripentol compare to other GABA modulators in managing Dravet Syndrome seizures?
What biomarkers are associated with response to Stiripentol in SCN1A-related Dravet Syndrome?
What are the potential adverse events of long-term Stiripentol use in pediatric epilepsy populations?
How do Stiripentol combination therapies impact seizure frequency in treatment-resistant Dravet Syndrome?
Trial Locations
- Locations (1)
Children's Hospital Colorado
🇺🇸Aurora, Colorado, United States
Children's Hospital Colorado🇺🇸Aurora, Colorado, United States